SecBot SecBot
SECBOTREPLAY Home › Report › KURA

KURA · Kura Oncology announced an oral presentation of updated Phase 1a data…

Kura Oncology, Inc. · PRESS-RELEASE filed Jul 14, 2026 at 07:02 ET

At the news

NEUTRALIMPACT 5/10

PRESS-RELEASE filed Jul 14, 2026 at 07:02 ET

Kura Oncology announced an oral presentation of updated Phase 1a data from its FIT-001 trial of darlifarnib plus cabozantinib in advanced ccRCC at the 2026 Kidney Cancer Research Summit. The data show long-term follow-up in heavily pretreated cabozantinib-naïve patients, supporting the combination's potential. A virtual investor call is scheduled for July 27, 2026, following the presentation.

  • Oral presentation at 2026 KCRS on July 24, 2026, featuring updated Phase 1a data from FIT-001 trial of darlifarnib + cabozantinib in advanced ccRCC.
  • Data are long-term follow-up in heavily pretreated, cabozantinib-naïve patients with refractory RCC.
  • Global randomized Phase 1b dose-optimization portion of FIT-001 (darlifarnib + cabozantinib vs. cabozantinib alone) is ongoing.
  • Registrational Phase 3 study planned for 2028.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access